EM1703Q "'I’ve Never Seen My Cholesterol So Low.' Lowering Cholesterol with PCSK9 Inhibitors"
The purpose of this presentation is to familiarize the audience with a new class of lipid lowering drugs: PCSK9 inhibitors.
The presentation will discuss the unmet needs (i.e. the large group of patients who require lipid lowering therapies in addition to statins), the history and current status of PCSK9 inhibitors, and the cardiovascular outcomes data from studies of PCSK9 inhibitors.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Recognize that a large number of patients with coronary heart disease fail to achieve their LDL-C goals.
- Appreciate that Familial Hypercholesterolemia (FH) is underdiagnosed in the US, and FH patients require lipid lowering therapies in addition to statin.
- Understand the similarities and differences between the two approved PCSK9 inhibitors.
- Know the cardiovascular outcomes data for PCSK9 inhibitors.
Zahid Ahmad, M.D.
Assistant Professor of Medicine
Division of Nutrition and Metabolic Diseases
- 1.00 AMA